Thymosin Beta-4 half-life & pharmacokinetics

Reported half-life

Approximately 1–2 hours terminal half-life (intravenous, Phase I human pharmacokinetics); rapid tissue distribution

The half-life and pharmacokinetic profile of Thymosin Beta-4 reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• subcutaneous injection
• intravenous infusion
• topical ophthalmic drops
• intraperitoneal injection (pre-clinical)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Actin-sequestering polypeptide; multi-tissue regenerative and cytoprotective agent

Mechanism context

Half-life interpretation depends on the underlying mechanism. Thymosin Beta-4 acts as follows:

Thymosin beta-4 is a 43-amino-acid ubiquitous intracellular protein that functions as the principal sequestrant of monomeric G-actin in mammalian cells. The approximately 15-fold molar excess of Tβ4 over the conventional actin-capping proteins means that it acts as a primary buffer of the intracellular G-actin pool, making monomeric actin available for rapid polymerisation at sites of cytoskeletal remodelling. By regulating this G-to-F actin dynamic equilibrium, Tβ4 governs the capacity of cells to form lamellipodia, migrate in response to chemotactic gradients, and remodel their cytoskeleton during division and wound response.

See the full Thymosin Beta-4 research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.